BeiGene, Ltd. (BGNE)
After hours:
| Previous Close | 201.86 |
| Open | 205.79 |
| Bid | 180.00 x 1100 |
| Ask | 189.30 x 800 |
| Day's Range | 183.84 - 206.82 |
| 52 Week Range | 118.18 - 325.45 |
| Volume | |
| Avg. Volume | 262,548 |
| Market Cap | 19.599B |
| Beta (5Y Monthly) | 0.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, November 22, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) a global biotechnology company, today announced that the results of the final progression free survival (PFS) analysis of the ALPINE trial will be presented at a late-breaking oral presentation session at the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans. ALPINE is a global Phase 3 trial comparing BRUKINSA (zanubrutinib) with IMBRUVICA® (ibrutinib) in pat
- Business Wire
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, November 17, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the European Commission (EC) has approved BRUKINSA® (zanubrutinib) for the treatment of adult patients with treatment-naïve (TN) or relapsed/refractory (R/R) CLL.
- Business Wire
BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer Care
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, November 15, 2022--BeiGene today announced the launch of a new program, Talk About It: Cancer and Mental Health.
